V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1

AIDS Research and Human Retroviruses

Volumn 17, Issue 18, 2001, Pages 1737-1748

  Krachmarov, Chavdar P ^a   Kayman, Samuel C ^a   Honnen, William J ^a   Trochev, Orlin ^a   Pinter, Abraham ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; CHROMATOGRAPHY, AFFINITY; GLYCOSYLATION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0035701793     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220152741432     Document Type: Article

References (47)

1. A vaccine for HIV type 1: The antibody perspective
2. Neutralizing epitopes of HIV-1
3. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement
4. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
5. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
6. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
7. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12
8. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody
9. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
10. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
11. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies
12. Characterization of neutralization epitopes in the V2 region of HIV-1 gp120: Role of conserved glycosylation sites in the correct folding of the V1/V2 domain
13. A novel glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent neutralizing chimpanzee monoclonal antibody
14. Synergistic neutralization of HIV-1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibody against the V3 loop and the CD4-binding site
15. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
16. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1
17. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120
18. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1
19. Neutralizing antibodies from sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140
20. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1
21. Presentation of native epitopes in the V1/V2 and V3 domains of HIV-1 gp120 by fusion glycoproteins containing fragments of gp120
22. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain
23. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors
24. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism
25. Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1
26. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development
27. Potent neutralization of primary HIV-1 isolates by antibodies directed against eiptopes present in the V1/V2 domain of HIV-1 gp120
28. A potent, neutralizing human monoclonal antibody against a unique epitoipe overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates
29. A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity
30. Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides
31. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
32. Characterization of a human cell line transformed by DNA from human adenovirus type 5
33. The role of mononuclear phagocytes in HTLV-III/LAV infection
34. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation
35. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1
36. Macrophage tropism determinants of human immunodeficiency virus type I in vivo
37. Genomic diversity of human T-lymphotropic virus type III (HTLV-III)
38. Molecular cloning of AIDS-associated retrovirus
39. Potent neutralization of a macrophage-tropic HIV-1 isolate by antibodies against the V1/V2 domain of gp120
40. Prevention of HIV infection by passive immunization with HIV immunoglobulin
41. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses
42. Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: Lack of correlation with viral phenotype
43. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1
44. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
45. Identification of envelope V3 loop as the primary determinant of cell tropism in HIV-1
46. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1